Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2009-01-19
2010-12-21
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S182000, C564S191000, C564S192000, C562S498000, C562S507000, C548S204000, C548S254000, C548S335500, C546S272700, C546S336000, C544S124000, C514S237800, C514S357000, C514S365000, C514S396000, C514S534000, C514S616000, C514S617000
Reexamination Certificate
active
07855308
ABSTRACT:
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
REFERENCES:
patent: 4273704 (1981-06-01), Mazur
patent: 4324791 (1982-04-01), Welstead, Jr.
patent: 4514332 (1985-04-01), Hansen, Jr. et al.
patent: 4751292 (1988-06-01), Fox
patent: 4921958 (1990-05-01), Abou-Gharbia et al.
patent: 5397788 (1995-03-01), Horwell et al.
patent: 5622983 (1997-04-01), Horwell et al.
patent: 6368816 (2002-04-01), Walker et al.
patent: 6784167 (2004-08-01), Wood et al.
patent: 7087400 (2006-08-01), Walker et al.
patent: 7122531 (2006-10-01), Walker et al.
patent: 7217838 (2007-05-01), Rohde et al.
patent: 7435833 (2008-10-01), Yeh et al.
patent: 7511175 (2009-03-01), Patel et al.
patent: 2004/0122033 (2004-06-01), Nargund et al.
patent: 2004/0133011 (2004-07-01), Waddell et al.
patent: 2005/0245534 (2005-11-01), Link et al.
patent: 2005/0261302 (2005-11-01), Hoff et al.
patent: 2005/0277647 (2005-12-01), Link et al.
patent: 2005/0288338 (2005-12-01), Yao et al.
patent: 2006/0004049 (2006-01-01), Yao et al.
patent: 2006/0009471 (2006-01-01), Yao et al.
patent: 2006/0009491 (2006-01-01), Yao et al.
patent: 2006/0079506 (2006-04-01), Linders et al.
patent: 2006/0089349 (2006-04-01), Gundertofte et al.
patent: 2006/0094699 (2006-05-01), Kampen et al.
patent: 2006/0100235 (2006-05-01), Andersen et al.
patent: 2006/0106008 (2006-05-01), Andersen et al.
patent: 2006/0106071 (2006-05-01), Lin et al.
patent: 2006/0111348 (2006-05-01), Kampen et al.
patent: 2006/0111366 (2006-05-01), Andersen et al.
patent: 2006/0281773 (2006-12-01), Patel et al.
patent: 2007/0161641 (2007-07-01), Hendrix et al.
patent: 2008/0064693 (2008-03-01), Jaroskova et al.
patent: 215297 (1987-03-01), None
patent: 336356 (1989-04-01), None
patent: 405537 (1990-06-01), None
patent: 564924 (1993-10-01), None
patent: 697403 (1996-02-01), None
patent: 1180513 (2002-02-01), None
patent: 740752 (1980-09-01), None
patent: 803348 (1981-09-01), None
patent: 9113081 (1991-09-01), None
patent: 9214697 (1992-09-01), None
patent: 9428885 (1994-12-01), None
patent: 9500146 (1995-01-01), None
patent: 9902145 (1999-01-01), None
patent: 0129007 (2001-04-01), None
patent: WO-03059905 (2003-07-01), None
patent: 200365983 (2003-08-01), None
patent: 2003075660 (2003-09-01), None
patent: 200411310 (2004-02-01), None
patent: 2004033427 (2004-04-01), None
patent: 2004037251 (2004-05-01), None
patent: 2004056744 (2004-07-01), None
patent: 2004056745 (2004-08-01), None
patent: 2004065351 (2004-08-01), None
patent: 2004089367 (2004-10-01), None
patent: 2004089380 (2004-10-01), None
patent: 2004089416 (2004-10-01), None
patent: 2004089470 (2004-10-01), None
patent: 2004089471 (2004-10-01), None
patent: 2004089896 (2004-10-01), None
patent: WO-2004113310 (2004-12-01), None
patent: 2005016877 (2005-02-01), None
patent: 2005042513 (2005-05-01), None
patent: 2005046685 (2005-05-01), None
patent: 2005047250 (2005-05-01), None
patent: 2005060963 (2005-07-01), None
patent: 2005097764 (2005-10-01), None
patent: 2005103023 (2005-11-01), None
patent: 2005108359 (2005-11-01), None
patent: WO-2005108361 (2005-11-01), None
patent: 2005116002 (2005-12-01), None
patent: 2006002349 (2006-01-01), None
patent: 2006002350 (2006-01-01), None
patent: 2006002361 (2006-01-01), None
patent: 2006012173 (2006-02-01), None
patent: 2006012226 (2006-02-01), None
patent: 2006012227 (2006-02-01), None
patent: 2006012642 (2006-02-01), None
patent: 2006017542 (2006-02-01), None
patent: 2006020598 (2006-02-01), None
patent: 2006024627 (2006-03-01), None
patent: 2006024628 (2006-03-01), None
patent: 2006040329 (2006-04-01), None
patent: 2006048330 (2006-05-01), None
patent: 2006048331 (2006-05-01), None
patent: 2006048750 (2006-05-01), None
patent: 2006049952 (2006-05-01), None
patent: 2006050908 (2006-05-01), None
patent: 2006053024 (2006-05-01), None
patent: 2006066109 (2006-06-01), None
patent: WO-2006104280 (2006-10-01), None
Bernard Testa “Predicting drug metabolism: Concepts and challenges” Pure and Applied Chemistry 2004, vol. 76. No. 5, pp. 907-914.
Albrecht S. et al., “Nonpituitary Tumors of the Sellar Region,” Cushing's Disease in:Melmed S. Ed. The Pituitary, 2002, pp. 592-612, 2nd Ed.
Billaudel B., “Immediate in-vivo effect of corticosterone on glucose-induced insulin secretion in the rat,” Journ of Endocrin, 1982, pp. 315-320, vol. 95.
Budziszewska., “Effect of antidepressant drugs on the hypothalamic-pituitary-adrenal axis activity and glucocorticoid receptor function,” Polish Journal of Pharm, 2002, pp. 343-349, vol. 54.
Cooper M.S. et al., “Modulation of 110-Hydroxysteroid Dehydrogenase Enzymes by Proinflammatory Cytokines in Osteoblasts: An Autocrine Switch from Glucocorticoid Inactivation to Activation,” J Bone Miner Res, 2001, pp. 1037-1044, vol. 16.
De Battista et al., “The use of mifepristone in the treatment of neuropsychiatric disorders,” Trends in Endoc. Metab, 2006, pp. 117-120, vol. 17.
Gomez Sanchez et al., “Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone,” AJP Endocrinology and Metabolism, 2006, pp. E1125-E1130, vol. 263 (6).
Harris, H.J. et al., “Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice,” Endocrinology, 2001, pp. 114-120, 142 (1).
Hong et al., “Synthesis and biological studies of novel neurotensin (8-13) mimetics,” Bioorganic & Medicinal Chemistry, 2002, pp. 3849-3858, vol. 10 (12).
International Search Report for application No. PCT/US2006/000210, Mailed on Aug. 11, 2006, 5 pages.
International Search Report for application No. PCT/US2006/000402, Mailed on Sep. 11, 2006, 6 pages.
International Search Report for application no. PCT/US2007/066125, Mailed on Sep. 21, 2007, 5 pages.
International Search Report for application No. PCT/US2008/073830, Mailed on Mar. 12, 2009, 5 pages.
Kerr D.S., “Modulation of hippocampal long-term potentiation and long-term depression by corticosteroid receptor activation,” Psychobiology, 1994, pp. 123-133, vol. 22.
Kershaw E.E., “Adipocyte-Specific Glucocorticoid Inactivation Protects Against Diet-Induced Obesity,” Diabetes, 2005, pp. 1023-1031, vol. 54.
Kim C. H. et al., “Effects of dexamethasone on proliferation, activity, and cytkine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoidinduced bone loss,” Journ of Endocrin, 1999, pp. 371-379, vol. 162.
Kolocouris N. et al., “Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives,” Journal of Medicinal Chemistry, 1996, pp. 3307-3318, vol. 39 (17).
Kozlowski J.A. et al., “Substituted 2-0-Methyl Piperazines as Muscarinic M2 Selective Ligands,” Bioorg & Medicin Chem Ltrs, 2002, pp. 791-794, vol. 12.
Lakshmi et al., “Regional Distribution of 11-beta-Hydroxysteroid Dehydrogenase in Rat Brain,” Endocrinology, 1991, 128 (4), 1741-1748.
Landfield.,“Hippocampal Cell Death,” Science, 1996, vol. 272, pp. 1249-1251.
Le Noble W.J. et al., “5-tert-Butyladamantan-2-one,” J Org Chem, 1983, pp. 1099-1101, vol. 48.
Mcewen., “Glucocorticoids, depression, and mood disorders: structural remodeling in the brain,” Metab. Clin. And Exp, 2005, vol. 54,pp. 20-23.
Moisan et al., “11-beta-Hydroxysteroid Dehydrogenase Bioactivity and Messenger RNA Expression in Rat Forebrain: Localization in Hypothalamus, Hippocampus, and Cortex,” Endocrinology, 1990, 127 (3), 1450-1455.
Monder et al., Vita
Brune Michael E.
Jacobson Peer B.
Link James T.
Patel Jyoti R.
Rohde Jeffrey J.
Abbott Laboratories
Kumar Shailendra
Vepachedu Sreenivasarao
LandOfFree
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178214